Posted by Michael Wonder on 16 Feb 2022
Pfizer and OPKO’s once weekly Ngenla (somatrogon) injection receives marketing authorisation in European Union for treatment of paediatric growth hormone deficiency
15 February 2022 - Pfizer and OPKO Health announced today that the European Commission has granted marketing authorisation for the next generation long-acting recombinant human growth hormone Ngenla (somatrogon), a once weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
Ngenla provides paediatric patients, their caregivers and health care providers with a new treatment option for growth hormone deficiency that reduces the frequency of required injections from once daily to once weekly.
